Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Moderate Buy” from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $48.38.

A number of research firms have recently commented on TARS. Barclays boosted their price target on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Lifesci Capital reiterated an “outperform” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, December 26th. Finally, Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $34.42 on Thursday. The stock’s fifty day moving average price is $33.78 and its two-hundred day moving average price is $24.16. The firm has a market cap of $1.18 billion, a PE ratio of -7.42 and a beta of 1.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85. Tarsus Pharmaceuticals has a one year low of $12.48 and a one year high of $40.40.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. As a group, research analysts expect that Tarsus Pharmaceuticals will post -4.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Aziz Mottiwala sold 4,766 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $145,839.60. Following the sale, the insider now directly owns 54,075 shares of the company’s stock, valued at approximately $1,654,695. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $149,297.40. Following the completion of the sale, the chief operating officer now directly owns 64,767 shares in the company, valued at $1,981,870.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Aziz Mottiwala sold 4,766 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $145,839.60. Following the completion of the transaction, the insider now directly owns 54,075 shares in the company, valued at $1,654,695. The disclosure for this sale can be found here. Insiders have sold a total of 24,496 shares of company stock valued at $749,578 over the last ninety days. 11.54% of the stock is owned by company insiders.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Ieq Capital LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter valued at approximately $193,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Tarsus Pharmaceuticals during the 3rd quarter valued at $723,000. Allspring Global Investments Holdings LLC raised its holdings in Tarsus Pharmaceuticals by 2,784.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 245,972 shares of the company’s stock worth $4,371,000 after buying an additional 237,445 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at $7,093,000. Finally, Swiss National Bank lifted its stake in shares of Tarsus Pharmaceuticals by 41.5% in the third quarter. Swiss National Bank now owns 49,433 shares of the company’s stock valued at $878,000 after buying an additional 14,500 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.